Tag:
darapladib
Latest Headlines
Latest Headlines
HGS faces skeptics as it boasts of a crowded bargaining table
Human Genome Sciences has prescribed a poison pill for GlaxoSmithKline's hostile takeover bid.
Glaxo goes hostile on HGS with $2.6B bid
Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.
GSK and HGS posture over price and value in M&A standoff
Human Genome Sciences is wasting no opportunity when it comes to touting its underlying value.
UPDATED: GSK puts Human Genome Sciences in play with $2.59B buyout offer
In moments speculators bid up HGS's battered share value by 110%, to more than $15, as HGS quickly rejected the offer.
Study highlights potential benefits of GSK heart drug
A way of fighting heart disease being pioneered by GlaxoSmithKline ( NYSE: GSK ) got a boost today from a scientific study that appears in The Lancet stressed the significance of an artery-clogging
GSK gambles on massive heart drug trial
While other companies are cutting back, GlaxoSmithKline is ramping up. The drugmaker announced on Thursday that it is initiating the first Phase III clinical trial for an investigational Lp-PLA2
